MA52490A - Anticorps présentant des profils de glycane modulés - Google Patents

Anticorps présentant des profils de glycane modulés

Info

Publication number
MA52490A
MA52490A MA052490A MA52490A MA52490A MA 52490 A MA52490 A MA 52490A MA 052490 A MA052490 A MA 052490A MA 52490 A MA52490 A MA 52490A MA 52490 A MA52490 A MA 52490A
Authority
MA
Morocco
Prior art keywords
glycane
antibodies
profiles
modulated
modulated glycane
Prior art date
Application number
MA052490A
Other languages
English (en)
Inventor
Michael Charles Brandenstein
Christopher Kenyon Crowell
Alison Jean Gillespie
Neil Anthony Kitchen
Athena Denise Nagi
Simina Crina Petrovan
Jian Wu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA52490A publication Critical patent/MA52490A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA052490A 2018-05-01 2019-04-30 Anticorps présentant des profils de glycane modulés MA52490A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862665045P 2018-05-01 2018-05-01

Publications (1)

Publication Number Publication Date
MA52490A true MA52490A (fr) 2021-03-10

Family

ID=66542532

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052490A MA52490A (fr) 2018-05-01 2019-04-30 Anticorps présentant des profils de glycane modulés

Country Status (16)

Country Link
US (1) US20210062156A1 (fr)
EP (2) EP4316519A3 (fr)
JP (1) JP2021521854A (fr)
KR (1) KR20210005689A (fr)
CN (1) CN112074537A (fr)
AU (1) AU2019263008A1 (fr)
BR (1) BR112020022166A2 (fr)
CA (1) CA3099163A1 (fr)
CL (1) CL2020002810A1 (fr)
EA (1) EA202092576A1 (fr)
IL (2) IL278211B1 (fr)
MA (1) MA52490A (fr)
MX (1) MX2020011614A (fr)
SG (1) SG11202010744YA (fr)
TW (1) TW202003574A (fr)
WO (1) WO2019213043A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202405159A (zh) * 2022-06-28 2024-02-01 美商安進公司 用於治療性產品製造的靈活的設施配置
CN117825686A (zh) * 2024-03-05 2024-04-05 军科正源（北京）药物研究有限责任公司 用于检测地诺单抗抗药性抗体的样品预处理方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159259A (en) * 1875-02-02 Improvement in reservoir cooking-stoves
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP2856159A4 (fr) * 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc Méthodes associées au denosumab
TWI625390B (zh) * 2013-03-14 2018-06-01 安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US8956830B2 (en) * 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
JP6668241B2 (ja) * 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子

Also Published As

Publication number Publication date
CN112074537A (zh) 2020-12-11
IL278211B1 (en) 2023-10-01
US20210062156A1 (en) 2021-03-04
EA202092576A1 (ru) 2021-02-05
EP3788076A1 (fr) 2021-03-10
CA3099163A1 (fr) 2019-11-07
IL278211A (en) 2020-11-30
AU2019263008A1 (en) 2020-11-19
WO2019213043A1 (fr) 2019-11-07
IL307155A (en) 2023-11-01
TW202003574A (zh) 2020-01-16
MX2020011614A (es) 2020-12-09
BR112020022166A2 (pt) 2021-01-26
CL2020002810A1 (es) 2021-02-19
JP2021521854A (ja) 2021-08-30
KR20210005689A (ko) 2021-01-14
EP4316519A2 (fr) 2024-02-07
SG11202010744YA (en) 2020-11-27
EP4316519A3 (fr) 2024-04-24

Similar Documents

Publication Publication Date Title
MA47268A (fr) Anticorps anti-gpc3
MA53434A (fr) Anticorps anti-tigit
MA45231A (fr) Anticorps anti-ige
MA46057A (fr) Anticorps anti-ctla4
CL2019002881S1 (es) Camión.
MA50373A (fr) Anticorps anti-c5 présentant une pharmacocinétique améliorée
MA46272A (fr) Anticorps anti-cd27
MA49749A (fr) Anticorps anti-cd137
MA52366A (fr) Anticorps anti-tl1a optimisés
DK3606961T3 (da) Garp-tgf-beta-antistoffer
MA52152A (fr) Anticorps
MA51134A (fr) Anticorps anti-alpha-synucléine
MA44236A (fr) Anticorps anti-tgfbêta 2
MA42137A (fr) Anticorps vhb anti-pre-s1
DK3479159T3 (da) Moduleret fabry-pérot
MA51135A (fr) Anticorps anti-alpha-synucléine
MA50654A (fr) Anticorps anti-pacap
MA56466A (fr) Anticorps anti-epha4
MA52490A (fr) Anticorps présentant des profils de glycane modulés
DK3478831T3 (da) Asparaginproteaser
MA49257A (fr) Anticorps anti-trkb
MA43869A (fr) Anticorps anti-myl9
MA56394A (fr) Anticorps anti-angpt2
MA55519A (fr) Anticorps anti-fgf23
CL2019003781S1 (es) Camión.